Cowen Reiterates Krystal Biotech (KRYS) at Outperform, $111 PT, Encouraged by Impressive Skin Changes of KB301 Which "FDA Places Significant Weight On"
Tweet Send to a Friend
Cowen analyst Ritu Baral reiterated an Outperform rating and $111.00 price target on Krystal Biotech (NASDAQ: KRYS), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
